PDI’s “Buy” Rating Reaffirmed at Roth Capital (PDII)
PDI (NASDAQ:PDII)‘s stock had its “buy” rating reaffirmed by analysts at Roth Capital in a research report issued to clients and investors on Friday. They currently have a $6.50 price objective on the stock, down from their previous price objective of $8.00. Roth Capital’s price target indicates a potential upside of 107.01% from the company’s current price.
PDI (NASDAQ:PDII) traded down 2.87% during mid-day trading on Friday, hitting $3.05. The stock had a trading volume of 93,354 shares. PDI has a one year low of $3.08 and a one year high of $6.25. The stock’s 50-day moving average is $3.99 and its 200-day moving average is $4.60. The company’s market cap is $45.5 million.
PDI (NASDAQ:PDII) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.05. The company had revenue of $31.60 million for the quarter, compared to the consensus estimate of $35.60 million. Analysts expect that PDI will post $-0.42 EPS for the current fiscal year.
PDI, Inc provides outsourced commercial services to established and emerging pharmaceutical, biotechnology and healthcare companies in the United States.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.